This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Szepeshazi, K. Articles by Szoke, B. Search for Related Content PubMed PubMed Citation Articles by Szepeshazi, K. Articles by Szoke, B.

Inhibitory Effect of Bombesin/Gastrin-releasing Peptide Antagonist RC-3095 and High Dose of Somatostatin Analogue RC-160 on Nitrosamine-induced Pancreatic Cancers in Hamsters¹

Section of Experimental Medicine, Department of Medicine, Tulane University Medical School [K. S., A. V. S., R-Z. C., S. R., S. M., B. S.], New Orleans 70112 and Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center [A. V. S.], New Orleans, Louisiana 70146

Female Syrian golden hamsters with N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancers were treated for 2 months with new pseudononapeptide bombesin receptor antagonist [D-Tpi⁶,Leu¹³(CH₂NH)-Leu¹⁴]bombesin(6-14)(RC-3095), administered s.c. with implanted osmotic minipumps releasing 20 µg/day of the analogue. The results were compared to those obtained by treatment with somatostatin analogue RC-160 (35 µg/day and 150 µg/day) or [D-Trp⁶]luteinizing hormone-releasing hormone (25 µg/day), which inhibited the growth of pancreatic cancers in our previous studies. A new acetylated somatostatin analogue Ac-D-
(RC-160-II) (30 µg/day) also was used for comparison of therapeutic response. All peptide analogues induced tumor inhibition by at least one of the measured parameters. Bombesin antagonist RC-3095 and high dose of RC-160 (150 µg/day) had the greatest inhibitory effect on pancreatic cancers: A significant decrease in the number of animals with tumors, reduced pancreatic weight, 87–89% inhibition of tumorous pancreas weight, and a significant diminution in the number of tumor nodules and argyrophilic nucleolar organizer region count in tumor cell nuclei were observed in the groups treated with these regimens. We were able to detect receptors for bombesin in membranes of N-nitrosobis(2-oxopropyl)amine-induced pancreatic tumors and these receptors were not down-regulated after treatment with the bombesin antagonist. In hamsters treated with bombesin antagonists, tumor inhibition might be explained by a significant decrease in the binding capacity of epidermal growth factor receptors in pancreatic cancers. The acetylated somatostatin analogue RC-160-II had a similar inhibitory effect on the tumors as the original analogue RC-160. Our results suggest that the increase in the dose of RC-160 improves the therapeutic response, and this finding should be taken into account in clinical use of this somatostatin analogue. In view of its strong inhibitory effect on experimental pancreatic tumors, the bombesin antagonist RC-3095 might be considered as a possible new agent for the therapy of human exocrine pancreatic cancer.

¹ This work was supported by NIH Grant CA 40077, the Medical Research Services of the Veterans Affairs, all to A. V. S.

² To whom requests for reprints should be addressed, at Veterans Affairs Medical Center, 1601 Perdido Street, New Orleans, LA 70146.

Received 5/ 8/91. Accepted 8/27/91.

This article has been cited by other articles:

				R. P. Thomas, M. R. Hellmich, C. M. Townsend Jr., and B. M. Evers Role of Gastrointestinal Hormones in the Proliferation of Normal and Neoplastic Tissues Endocr. Rev., October 1, 2003; 24(5): 571 - 599. [Abstract] [Full Text] [PDF]

				I. Chatzistamou, A. V. Schally, J. L. Varga, K. Groot, P. Armatis, R. Busto, and G. Halmos Antagonists of Growth Hormone-Releasing Hormone and Somatostatin Analog RC-160 Inhibit the Growth of the OV-1063 Human Epithelial Ovarian Cancer Cell Line Xenografted into Nude Mice J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2144 - 2152. [Abstract] [Full Text]

				K. Szepeshazi, A. V. Schally, G. Halmos, N. Lamharzi, K. Groot, and J. E. Horvath A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers PNAS, September 30, 1997; 94(20): 10913 - 10918. [Abstract] [Full Text] [PDF]